Efficacy and safety of potassium binders in the treatment of patients with chronic kidney disease and hyperkalemia

高钾血症 肾脏疾病 医学 内科学 疾病 重症监护医学 化学 有机化学
作者
Lingqiu Dong,Weidong Xu,Yi Deng,Jiaxing Tan,Wei Qin
出处
期刊:European Journal of Pharmacology [Elsevier BV]
卷期号:931: 175174-175174 被引量:15
标识
DOI:10.1016/j.ejphar.2022.175174
摘要

Gastrointestinal cation exchangers that can bind potassium in the gut, including sodium polystyrene sulfonate (SPS), calcium polystyrene sulfonate (CPS), patiromer and sodium zirconium cyclosilicate (SZC), are emerging medications for the treatment of hyperkalemia with chronic kidney disease (CKD). However, which might be the best alternative for patients with chronic kidney disease and hyperkalemia remains disputed. We performed this systematic review and network meta-analysis with the Bayesian approach to conduct direct and indirect comparisons among potassium binders regarding their efficacy and safety. The surface under the cumulative ranking curve analysis (SUCRA) was used to calculate the best intervention for each outcome. All four potassium binders had a promising effect regarding potassium reduction. SPS had favorable efficacy and safety for short-term use (MD: −0.94; 95% CIs: −1.4 to −0.48; SUCRA = 94.69%), but long-term treatment required strict dose control and assessment of gastrointestinal conditions. CPS had a positive effect on reducing potassium, and could especially maintain the serum potassium concentration in patients receiving renin-angiotensin-aldosterone system inhibitors (RAASi). Patiromer might reduce all-cause mortality in CKD patients with hyperkalemia and have a positive effect on potassium-lowering, though it had significant gastrointestinal adverse effects. SZC had a potassium-lowering effect in both the short-term and long-term, and can be a promising long-term treatment for the hyperkalemia in CKD patients, especially in combination with RAASi. These four potassium binders had their own advantages and disadvantages, and the medication should be selected according to the clinical situation of the patient.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
让我瞅瞅发布了新的文献求助10
刚刚
无奈的翅膀完成签到 ,获得积分10
3秒前
JamesPei应助Gao采纳,获得10
4秒前
安可完成签到 ,获得积分10
4秒前
阳立宇关注了科研通微信公众号
5秒前
他克莫司完成签到,获得积分10
7秒前
夏傥完成签到,获得积分10
7秒前
8秒前
9秒前
Steven发布了新的文献求助30
11秒前
英姑应助昏睡的铭采纳,获得10
11秒前
不想看文献完成签到,获得积分10
12秒前
干净的寒天完成签到,获得积分10
13秒前
14秒前
14秒前
诚心谷南发布了新的文献求助10
15秒前
16秒前
烟花应助第三人称的自己采纳,获得10
17秒前
dmm完成签到 ,获得积分10
18秒前
18秒前
ycc完成签到,获得积分10
18秒前
18秒前
18秒前
嘻嘻哈哈眼药水完成签到,获得积分10
19秒前
企鹅完成签到,获得积分10
19秒前
_Y_X_L_完成签到,获得积分10
19秒前
阳立宇发布了新的文献求助10
20秒前
20秒前
科研通AI2S应助shuaishuyi采纳,获得10
21秒前
嘀嘀咕咕发布了新的文献求助10
22秒前
DT发布了新的文献求助10
22秒前
悟空应助陈强强采纳,获得10
24秒前
lina发布了新的文献求助10
24秒前
25秒前
Bebetter完成签到,获得积分10
25秒前
Peggy发布了新的文献求助10
25秒前
26秒前
Slhy完成签到 ,获得积分10
26秒前
27秒前
大喵发布了新的文献求助10
27秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989797
求助须知:如何正确求助?哪些是违规求助? 3531910
关于积分的说明 11255394
捐赠科研通 3270563
什么是DOI,文献DOI怎么找? 1805008
邀请新用户注册赠送积分活动 882157
科研通“疑难数据库(出版商)”最低求助积分说明 809190